2928-00-9

Usage

Uses

Used in Pharmaceutical Research and Development:
4-(4-FLUORO-PHENYL)-5-METHYL-THIAZOL-2-YLAMINE is used as a research compound for exploring its potential properties and applications in the pharmaceutical industry. Its unique molecular structure, which includes a thiazole ring, a fluorinated benzene ring, a methyl group, and an amine group, may offer valuable insights for the development of new drugs or drug candidates.
Used as an Intermediate in Pharmaceutical Synthesis:
In the pharmaceutical industry, 4-(4-FLUORO-PHENYL)-5-METHYL-THIAZOL-2-YLAMINE can be used as an intermediate in the synthesis of various pharmaceutical drugs. Its distinct chemical structure may contribute to the development of novel drug molecules with specific therapeutic properties or improved pharmacokinetic profiles.

InChI:InChI=1/C10H9FN2S/c1-6-9(13-10(12)14-6)7-2-4-8(11)5-3-7/h2-5H,1H3,(H2,12,13)

Upstream product

• 345-94-8 2-bromo-1-(4-fluorophenyl)propan-1-one 
• 17356-08-0 thiourea 
• 456-03-1 1-(4-fluorophenyl)propan-1-one 

Downstream Products

• 27225-22-5 2-fluoro-4-(4-fluoro-phenyl)-5-methyl-thiazole 
• 1827-81-2 5-fluoro-N-[4-(4-fluoro-phenyl)-5-methyl-thiazol-2-yl]-2-methyl-benzenesulfonamide 
• 1766-40-1 4-fluoro-N-[4-(4-fluoro-phenyl)-5-methyl-thiazol-2-yl]-benzenesulfonamide 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools

The most common CF mutation, F508del, impairs the processing and gating of CFTR protein. This deletion results in the improper folding of the protein and its degradation before it reaches the plasma membrane of epithelial cells. Present correctors, like VX809 only induce a partial rescue of the mutant protein. Our previous studies reported a class of compounds, called aminoarylthiazoles (AATs), featuring an interesting activity as correctors. Some of them show additive effect with VX809 indicating a different mechanism of action. In an attempt to construct more interesting molecules, it was thought to generate chemically hybrid compounds, blending a portion of VX809 merged to the thiazole scaffold. This approach was guided by the development of QSAR analyses, which were performed based on the F508del correctors so far disclosed in the literature. This strategy was aimed at exploring the key requirements turning in the corrector ability of the collected derivatives and allowed us to derive a predictive model guiding for the synthesis of novel hybrids as promising correctors. The new molecules were tested in functional and biochemical assays on bronchial CFBE41o-cells expressing F508del-CFTR showing a promising corrector activity.

Synthesis and antimicrobial activities of some novel 2,3-substituted-1,3-thiazolidin-4-ones derived from 2-amino-1,3-thiazole

New 2,3-substituted-1,3-thiazolidin-4-one (6a-f) were prepared by cyclocondensation of 2-[6-(4-chlorobenzyloxy)-2-naphthyliden]-4-(4-substituted phenyl)-5-methyl-1,3-thiazole (5a-f) and mercaptoacetic acid in benzene. The synthesized compounds were charac

UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF

The present invention provides compounds of formula (I): in which R 1, R'1, R2, R'2, R3, Y and G have the meanings given in the description, to a process for their preparation, their application by way of medicaments, and to pharmaceutical compositions containing them.